A Pan-Asian Clinical Database of EGFR Exon 20 Insertion Mutated NSCLC

Launched by NATIONAL CANCER CENTRE, SINGAPORE · May 16, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a specific type of lung cancer called advanced non-small cell lung cancer (NSCLC) that has a mutation known as EGFR exon 20 insertion. The goal is to better understand how this mutation affects patients in Asia, including how it responds to new targeted treatments. Researchers hope to gather detailed information about the disease's characteristics and outcomes for patients with this mutation, as there isn't much existing data on this topic in the region.

To be eligible for the trial, participants must be adults diagnosed with advanced NSCLC who have a confirmed EGFR exon 20 insertion mutation. This means they should have been tested and received a positive result from approved methods such as specific genetic tests. The study is currently looking for participants and aims to follow them for at least 12 months to see how they respond to treatment. If you or someone you know has this type of lung cancer and meets the criteria, participating in this trial could contribute to valuable insights that may help future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Histologically confirmed advanced NSCLC
• • 2. Positive testing result from any locally approved test (including but not limited to RT-PCR, Cobas and NGS) for EGFR exon 20 insertion mutation
• • 3. Diagnosis date from 1 Jan 2013 to 31 Dec 2022 (to allow for minimum 12 months of follow-up clinical and treatment outcome data)
• • 4. Male or female adults, age as defined by local regulations
• Exclusion Criteria:
• • 1. Patients without an EGFR exon 20 insertion mutation

Trial Officials